The Effect of rTMS to the Prefrontal Cortex in Alcohol Use Disorder

Alcohol Use Disorder Clinical Trial

— MAGNA  

Official title:

The Effect of rTMS to the Prefrontal Cortex in Alcohol Use Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03809286
• Other study ID #: 7691
• Secondary ID: 1K23AA0282955R21
• Status: Recruiting
• Phase: N/A
• Start date: June 24, 2019
• Est. completion date: December 30, 2024

Study information

• Verified date: February 2024
• Source: New York State Psychiatric Institute
• Contact: Jonathan Wai, MD
• Phone: 646-774-7654
• Email: jonathan.wai[@]nyspi.columbia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to investigate a treatment approach for alcohol use disorder (AUD) using a novel form of brain stimulation called deep repetitive transcranial magnetic stimulation (rTMS). The investigators will be targeting frontal regions of the brain that are important for memory and decision making. These brain regions have been shown to be impaired in patients with AUD. Previous studies have mostly used rTMS to a different frontal brain region that is not as deep. These studies have shown that rTMS can reduce craving for alcohol, but there is a lack of research showing that rTMS impacts alcohol consumption.

Description:

This study aims to examine the effect of rTMS on alcohol drinking behavior in an observed laboratory setting. Participants with AUD will be recruited and admitted to the inpatient unit for the whole study. After a brief detoxification period, they will receive 3 weeks of rTMS while in the research unit. Before and after the 3 weeks of stimulation, participants will participate in a decision-making experiment where they can choose to have an alcoholic drink or the equivalent amount of money that the drink would cost (alcohol self-administration sessions). The investigators will examine their response to alcohol, as well as their performance on tasks that relate to impulsivity and memory. Participants will also undergo an MRI scan (with spectroscopy) before and after the stimulation period to look at changes in the medial prefrontal cortex of the brain. Participants will then meet with a study physician for 6 weeks after the study for assessments of alcohol use and medical management sessions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Current moderate to severe alcohol use disorder, per DSM-5

2. Use of alcohol which parallels or exceeds the amount alcohol that will be administered in this study (1 drinking episode per week raising BAL to 0.03 g/dl - approximately 2 drinks within an hour).

3. Age 22-55

4. Able to give informed consent, and comply with study procedures

5. Medically healthy, with the absence of current or past medical or neurological illnesses (including glaucoma, increased intracranial pressure, liver disease, cardiac disease, or seizure disorders)

Exclusion Criteria:

1. Has a contraindication to MRI, such as magnetically reactive implants, which includes metal in head except in mouth (cochlear implant, implanted brain stimulators, aneurysm clips), cardiac pacemakers, implanted neurostimulators and medication pumps, and intracardiac lines.

2. Substance use disorder with substances other than alcohol or nicotine. The current use of sedative-hypnotics or opiates will be exclusionary

3. Meets DSM-5 criteria for other psychiatric illness, such as major depression, that would interfere with participation.

4. History of seizures of any type

5. A family history of epilepsy

6. Taking psychotropic medication that would affect resting motor threshold (such as anticonvulsants) or increase risk of seizure (especially tricyclic antidepressants of neuroleptics)

7. Current suicide risk or a history of suicide attempt within the past 2 years

8. Have unstable physical disorders, including those that are previously undiagnosed, untreated, inadequately treated, or active to an extent which might make participation hazardous. For example, hypertension (a resting blood pressure > 140/90), heart failure, a recent history of myocardial infarction, previous stroke, brain lesions, any history of seizures under any circumstances or low hemoglobin.

9. Currently pregnant

10. History of severe alcohol withdrawal requiring medical care, such as withdrawal seizures, delirium tremens, withdrawal necessitating medical detoxification.

11. A desire to pursue standard treatment for AUD, such as a rehabilitation program or FDA approved medications for AUD

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism

Intervention

Device:
• active rTMS
rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.

Behavioral:
• Inpatient admission
All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.

Device:
• sham rTMS
The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.

Locations

Country	Name	City	State
United States	New York State Psychiatric Institute	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
New York State Psychiatric Institute	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the choice to self-administer alcohol in the laboratory as assessed by counting the number of drinks consumed in the 2-hour laboratory session.	Participants will participate in alcohol self-administration sessions in which they are presented with the choice of alcohol or money. The investigators will study the change in choices to choose alcohol during these sessions. There will be one session prior to rTMS and one after 3 weeks of rTMS.	4 weeks
Primary	Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0.	Adverse events will be assessed in recorded in accordance with CTCAE v4.0.	10 weeks
Secondary	Change in craving for alcohol measured using the Alcohol Urge Questionnaire (AUQ).	This AUQ (Bohn et al. 1995) is an 8-item self report questionnaire where participants rate a seven-point Likert scale with responses ranging from "strongly disagree" to "strongly agree", and a total score is derived from the sum of these items following reverse scoring of two items. A lower score is a better outcome which represents less desire to drink. Scores range from 8-56.	4 weeks
Secondary	Change in GABA in the mPFC and ACC as measured with magnetic resonance spectroscopy (MRS).	MRS is performed by using an MRI machine to study metabolites and neurotransmitters in the brain.	4 weeks
Secondary	Change in abstinence from alcohol following discharge assessed with the Time Line Follow Back Interview.		10 weeks
Secondary	Changes in cognitive control as measured by using the Frontal Assessment Battery (FAB).	The FAB is a brief tool that discriminates between frontal-temporal type cognitive issues from from Alzheimer's type memory issues. Higher scores are better and scores range from 0-18.	4 weeks